Cat. No：GM-87130MAB
Product：Anti-HER2 hIgG1 Reference Antibody(Marbio)
Cat. No：GM-87130MAB
Product：Anti-HER2 hIgG1 Reference Antibody(Marbio)
GM-87130MAB-1mg / 1 mg
GM-87130MAB-5mg / 5 mg
GM-87130MAB-25mg / 25 mg
GM-87130MAB-50mg / 50mg
GM-87130MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target Her2
Clone Margetuximab
Alternative Names CD340, HER-2, HER-2/neu, ERBB2, MLN 19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2
Source/Isotype Human IgG1(RDEL), Kappa
Application Flow Cytometry
Description Human epidermal growth factor 2 is also known as erbB-2 and Neu; it is a member of the ErbBs or type I receptor tyrosine kinase family, which also includes the epidermal growth factor receptor 1 (EGFR or HER1), erbB-3 (HER3), and erbB-4 (HER4). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers. Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase. ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy.
Formulation Phosphate-buffered solution, pH 7.4.
Cat. No：GM-87130MAB
Product：Anti-HER2 hIgG1 Reference Antibody(Marbio)
GM-87130MAB-1mg / 1 mg
GM-87130MAB-5mg / 5 mg
GM-87130MAB-25mg / 25 mg
GM-87130MAB-50mg / 50mg
GM-87130MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target Her2
Clone Margetuximab
Alternative Names CD340, HER-2, HER-2/neu, ERBB2, MLN 19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2
Source/Isotype Human IgG1(RDEL), Kappa
Application Flow Cytometry
Description Human epidermal growth factor 2 is also known as erbB-2 and Neu; it is a member of the ErbBs or type I receptor tyrosine kinase family, which also includes the epidermal growth factor receptor 1 (EGFR or HER1), erbB-3 (HER3), and erbB-4 (HER4). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers. Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase. ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy.
Formulation Phosphate-buffered solution, pH 7.4.
